BlossomHill Therapeutics, Inc. (BLSM) Stock

NASDAQ: BLSMHealthcare company in the biotechnology industry, based in San Diego, CA.

BlossomHill Therapeutics stock price chart

BLSM interactive chart →

BLSM stock quote & key statistics

BlossomHill Therapeutics earnings per share

Income →
Earnings per share

BlossomHill Therapeutics revenue & net income

Income →
RevenueNet income

BlossomHill Therapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$60.6M—
FY2024$0-$30.7M—

Fiscal year ending December 31. Source: company filings via EODHD.

About BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

BlossomHill Therapeutics stock FAQ

What is the BlossomHill Therapeutics stock ticker symbol?

BlossomHill Therapeutics, Inc. trades on the NASDAQ under the ticker symbol BLSM.

What sector and industry is BlossomHill Therapeutics in?

BlossomHill Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does BlossomHill Therapeutics have?

BlossomHill Therapeutics, Inc. has about 69 full-time employees.

What were BlossomHill Therapeutics's revenue and earnings last fiscal year?

BlossomHill Therapeutics reported revenue of $0 and net income of -$60.6M in fiscal 2025.

When did BlossomHill Therapeutics go public?

BlossomHill Therapeutics stock began trading on August 7, 2026.

Biotechnology stocks

All Healthcare stocks →